title: Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA.
abstract: Further development of haematopoietic stem cell (HSC) gene therapy will depend on enhancement of gene transfer safety: ad hoc improvement of vector design relating to each particular disease is thus a crucial issue for HSC gene therapy. We modified a previously described lentiviral vector by adding the Emumar B-specific enhancer to a human CD19 promoter-derived sequence (Mol Ther 2004;10:45-56). We thus significantly improved the level of expression of the green fluorescent protein (GFP) reporter gene while retaining the specificity of expression in B-cell progeny of transduced human CD34+ progenitor cells obtained from cord blood or adult bone marrow. Indeed, GFP was strongly expressed from early medullary pro-B cells to splenic mature B cells whereas transgene expression remained low in transduced immature progenitors as in myeloid and T-lymphoid progeny retrieved from xenografted NOD/SCID/gammac(null) mice. Using this lentiviral vector, we further demonstrated the possibility to express a functional human BTK protein in long-term human CD34+ cell B-lymphoid progeny. This newly designed lentiviral vector fulfils one of the pre-requisites for the development of efficient and safe gene therapy for X-linked agammaglobulinaemia, the most common primary humoral immunodeficiency disorder.
authors.affiliation: Institut Paoli-Calmettes, Centre de Thérapie Cellulaire et Génique, Centre Régional de Lutte Contre le Cancer, Marseille, France.
authors.forename: T
authors.initials: T
authors.lastname: Moreau
authors.forename: V
authors.initials: V
authors.lastname: Barlogis
authors.forename: F
authors.initials: F
authors.lastname: Bardin
authors.forename: J A
authors.initials: JA
authors.lastname: Nunes
authors.forename: B
authors.initials: B
authors.lastname: Calmels
authors.forename: C
authors.initials: C
authors.lastname: Chabannon
authors.forename: C
authors.initials: C
authors.lastname: Tonnelle
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000361:Agammaglobulinemia / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D000818:Animals; D018952:Antigens, CD34 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D002460:Cell Line; D002478:Cells, Cultured; D015870:Gene Expression; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D049452:Green Fluorescent Proteins / Q000235:genetics; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000378:metabolism; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D051379:Mice; D016513:Mice, SCID; D023421:Models, Animal; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D014161:Transduction, Genetic / Q000379:methods; D019076:Transgenes; D014183:Transplantation, Heterologous
chemical_list: D018952:Antigens, CD34; D049452:Green Fluorescent Proteins; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human